Prospective risk analysis of urine micro-protein

doi:10.3969/j.issn.1673-8640.2017.011.005

Abstract

Abstract:

Objective To investigate and evaluate the risk of urine micro-protein determinations in clinical test and application. Methods The risk of urine micro-protein determinations,including the determinations of microv albumin（mAlb）,IgG,transferrin（Trf）,alpha₁-microglobulin（α₁-MG） and beta₂-microglobulin（β₂-MG）,in pre-analytical process,intra-analytical process and post-analytical process was evaluated by prospective risk analysis（PRA）. The main failures in urine micro-protein determinations included inappropriate preparation of patients,identification errors,inappropriate sample handling,delayed analysis,inappropriate analysis,inappropriate reporting and misunderstanding of results. The risk analysis concerned the probability（P） of failure occurring,the consequence（C） of failure and the chance of determining（D）. P and C scored on a scale of 0-10,and D scored on a scale of 1-3. The overall risk score（R） is calculated according to R=P×C. The risk was classified by the scores of R and D into acceptable,unacceptable and suboptimal levels. Then,a fishbone diagram outlined the cause and effect of unacceptable or suboptimal risk. Main causes were selected by discussion. Results No unacceptable risk was identified in urine micro-protein determinations. There were 2 items of suboptimal risk,which were inappropriate analysis and delayed analysis of β₂-MG. Fishbone diagram illustrated the main cause of inappropriate analysis was lacking of quality control. No determination at night and weekend was the main cause for the delayed analysis of β₂-MG. Conclusions PRA can identify risk effectively. It should take measures for mitigating or preventing risks by analyzing the main causes of unacceptable and suboptimal risks.

Key words: Micro-protein, Urine, Prospective risk analysis, Fishbone diagram

CLC Number:

R446.1

CHEN Yiqiong, ZHAO Di, DENG Xiaogang, REN Fang, XU Long, LI Zhi. Prospective risk analysis of urine micro-protein[J]. Laboratory Medicine, 2017, 32(11): 962-965.

Figures/Tables 3

References 10

[1]	ISO 15189:2012 医学实验室质量和能力认可准则[S].2012.
[2]	Clinical and Laboratory Standards Institute. Laboratory quality control based on risk management[S]. EP23-A,CLSI,2014.
[3]	JANSSENS P M.Practical,transparent prospective risk analysis for the clinical laboratory[J]. Ann Clin Biochem,2014,51(Pt 6):695-704.
[4]	JANSSENS P M,CHEUNG K S.Approaching risk analysis and risk management in the fertility laboratory and semen bank[J]. Int J Androl,2009,32(6): 656-665.
[5]	康凤凤,王薇,王治国. 风险管理与临床实验室质量改进[J]. 实验与检验医学,2013,31(1):1-3.
[6]	HAMMERLING J A.A review of medical errors in laboratory diagnostics and where we are today[J]. Lab Med,2012,43(2):41-44.
[7]	王国政,周华君,金美彤,等. 尿β2-微球蛋白测定影响因素的实验评价及纠正方法[J]. 现代检验医学杂志,2013,28(1):111-113.
[8]	韩宏艳,张敏,李晓伟,等. β2-微球蛋白测定的影响因素探讨及祛除方法[J]. 临床合理用药杂志,2010,3(19):133.
[9]	解冰,江利萍,王军,等. 自制尿微量蛋白质控液测定的应用[J]. 实验与检验医学,2014,32(5):545-546.
[10]	程定国. 尿微量白蛋白排除率的生理变动及有关因素探讨[J]. 检验与诊断,2013,12(2):132-133.

[1]	WANG Gangqiang, DIAO Yanjun, HE Juan, YANG Ruofan, YAN Hongbin, WANG Pei, LU Pei, LI Chenghua, XIAO Fengjing, ZHENG Shanluan, HAO Xiaoke, CHENG Xiang, LIU Jiayun. Establishment，verification and clinical application of automatic urine analysis system audit rule [J]. Laboratory Medicine, 2023, 38(10): 957-966.
[2]	WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99.
[3]	PAN Fen, PAN Yuxuan, SHI Yingying, YU Fangyuan, ZHANG Hong. UroQuick rapid urine culture technique for urinary tract infection in children [J]. Laboratory Medicine, 2022, 37(7): 652-656.
[4]	Danqu, Luosangcizhen, Zerenqucuo, MA Chaochao, LIU Zhijuan. Combined detection of urinary total protein to avoid the hook effect of urinary microalbumin [J]. Laboratory Medicine, 2021, 36(5): 477-479.
[5]	WANG Jinduo, CUI Yunqing, ZHANG Hui, Yanhua, LI Yinghua. Effect of vulva cleaning operation to the determination results of urinary biochemical indexes [J]. Laboratory Medicine, 2021, 36(11): 1169-1171.
[6]	XIAO Nan, ZHOU Jia, DUAN Ning, ZHU Tianyang, WANG Lijun. Establishment and evaluation of fast predictive algorithm for urinary tract infection pathogen in patients with nephrolithiasis [J]. Laboratory Medicine, 2021, 36(1): 75-79.
[7]	ZHOU Xin, ZHANG Jue, CHEN Liying. Study on the main causes for false increasing of white blood cells and small round epithelial cells determined by UF-1000i urine sediment analyzer [J]. Laboratory Medicine, 2020, 35(5): 444-446.
[8]	ZHOU Xin, ZHANG Jue, CHEN Liying. Study on the main causes for false increasing of white blood cells and small round epithelial cells determined by UF-1000i urine sediment analyzer [J]. Laboratory Medicine, 2020, 35(5): 444-446.
[9]	YANG Meiling, LIU Hao, YANG Lin, ZHU Ping. Research progress on the biomarkers of urinary tract infection [J]. Laboratory Medicine, 2020, 35(2): 178-180.
[10]	YU Shuping, YUAN Dandan, CUI Ming, JING Rongrong, WANG Huimin. Development of BCR-ABL1 candidate reference material and evaluation of measurement uncertainty [J]. Laboratory Medicine, 2019, 34(8): 752-757.
[11]	WANG Xueying, LIU Huan, ZHOU Xiang, YANG Ruofan, WANG Chun'e, MA Lian, BAI Bifeng, LI Feng. Role of urinary aquaporin 2 in evaluating proximal tubular injury [J]. Laboratory Medicine, 2019, 34(7): 626-629.
[12]	WEI Yongtao, WANG Songxia. Analysis of urinary iodine levels of pregnant women in Qingdao [J]. Laboratory Medicine, 2019, 34(10): 905-907.
[13]	TIAN Guoli, ZHOU Zhuo, GUO Jing, WANG Yanmin, JI Wei. Role of gas chromatography-mass spectrometry in inherited metabolic diseases [J]. Laboratory Medicine, 2019, 34(10): 932-936.
[14]	YING Xiao, WANG Yuying, WANG Zaihong, WANG Zhenhua. Influence of baicalein on in vitro anti-tumor activity of docetaxel for prostate cancer [J]. Laboratory Medicine, 2018, 33(6): 556-562.
[15]	WANG Lei, CHEN Weiqin, XU Minyi, CHEN Xudong. Establishment of magnetic particle chemiluminescence for the determination of urinary type Ⅳ collagen and its clinical application in membranous nephropathy [J]. Laboratory Medicine, 2018, 33(5): 442-446.